A randomized, double-blind, parallel group placebo-controlled study of the safety and reduction of signs and symptoms during treatment with tocilizumab (TCZ) [Actemra; Roche] versus placebo in patients with ankylosing spondylitis who have had an inadequate response to previous TNF [tumour necrosis factor] antagonist therapy.

Trial Profile

A randomized, double-blind, parallel group placebo-controlled study of the safety and reduction of signs and symptoms during treatment with tocilizumab (TCZ) [Actemra; Roche] versus placebo in patients with ankylosing spondylitis who have had an inadequate response to previous TNF [tumour necrosis factor] antagonist therapy.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Therapeutic Use
  • Acronyms BUILDER-2
  • Sponsors Roche
  • Most Recent Events

    • 13 Jun 2013 Results published in the Annals of the Rheumatic Diseases.
    • 08 Apr 2013 New source identified and integrated (Clinical Trials Registry - India: CTRI2011-04-001692).
    • 30 Sep 2011 Status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top